September 29, 2015 Analyst News 0 Comments
Akebia Therapeutics Receives a Buy from Brean Capital
By George Macdonald
Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Akebia Therapeutics (NASDAQ: AKBA) today and set a price target of $26. The company’s shares opened today at $9.76.
Aschoff wrote, “We recently hosted management meetings with Akebia and frequently occurring discussion themes included the competitive advantage for vadadustat in anemia related to CKD, Akebia’s partnership strategy and timing, details regarding both Phase 2 data sets, and Phase 3 design, timing and funding. We believe that the vadadustat Phase 2 results describe a differentiated anemia drug that can be safely and effectively administered with convenient dosing flexibility.”
on October last year was caused by the assumption that the drug is unsafe. with latest data. we are about to close that gap. not to mention the partners that will be signed for phase 3. on our way to 30 dollar
I remember they say its third quarter. with this data I think they are eager to sign. Europe partner before year end and 1 billion market cap 3 times current price per share
they have near 9 million shares at 8.25 watch the vol when it cross 13 or 14 million.
once those get cleared we make our run to the 20s